HONG KONG – Having been developing basic fibroblast growth factor (bFGF) products for more than 25 years, China’s Essex Bio-technology Ltd. (HK:1061) has earned a leading position in the ophthalmology biopharmaceutical space. Now the company is looking to expand its offerings by moving into the rapidly growing monoclonal antibody space.
HONG KONG – Having been developing basic fibroblast growth factor (bFGF) products for more than 25 years, China's Essex Bio-technology Ltd. (HK:1061) has earned a leading position in the ophthalmology biopharmaceutical space. Now the company is looking to expand its offerings by moving into the rapidly growing monoclonal antibody space.
HONG KONG – In a first release of its kind, the CFDA posted two lists of drugs set for fast lane approval through the Center for Drug Evaluation (CDE). This is the first time drugs by foreign companies have been given priority since the launch of a pilot priority review process proposed earlier this year. The project is part of a strategy to clear a backlog of applications.
HYDERABAD, India – A number of drug companies in India may have to repeat expensive clinical trials after Bangalore-based contract research organization (CRO) Semler Research Center Pvt. Ltd. received warnings from both the World Health Organization (WHO) and the FDA in April over data manipulation.
HONG KONG – In a first release of its kind, the CFDA posted two lists of drugs set for fast lane approval through the Center for Drug Evaluation (CDE). This is the first time drugs by foreign companies have been given priority since the launch of a pilot priority review process proposed earlier this year. The project is part of a strategy to clear a backlog of applications.
